Insilico, SK Launch Up-to-$2.5B Neuroimmune AI Drug Collaboration

Insilico Medicine and SK Biopharmaceuticals have entered a research collaboration valued at up to $2.5 billion to develop AI-driven treatments for neuroimmune disorders. The partnership will utilize Insilico’s generative AI platform to identify and design new therapeutic targets for conditions affecting the brain. By integrating AI into the drug discovery process, the companies aim to accelerate the development of treatments for diseases currently lacking effective medical options.